Ocular allergy treatment comparisons: Azelastine and olopatadine

Current Allergy and Asthma Reports

Volumn 4, Issue 4, 2004, Pages 320-325

  Bielory, Leonard ^a   Buddiga, Praveen ^a   Bigelson, Stephen ^a  

^a INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; AZELASTINE; CLEMASTINE; CORTICOSTEROID; CYCLOSPORIN; DESLORATADINE; DIPHENHYDRAMINE; EMEDASTINE; EPINASTINE; HISTAMINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; KETOTIFEN; MEPYRAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; OLOPATADINE; PLACEBO; TACROLIMUS; TRYPTASE; VASOCONSTRICTOR AGENT;

ALGORITHM; ALLERGIC CONJUNCTIVITIS; ALLERGIC DISEASE; ANTIINFLAMMATORY ACTIVITY; BITTER TASTE; BURNING SENSATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TOLERABILITY; EYE DISEASE; EYE INFLAMMATION; HUMAN; IC 50; KERATOCONJUNCTIVITIS; MAST CELL; MEDIATOR; MOLECULAR STABILITY; NONHUMAN; NOSE IRRITATION; OCULAR PRURITUS; REVIEW; RHINOCONJUNCTIVITIS; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT PLANNING; VERNAL CONJUNCTIVITIS;

EID: 5444258861     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-004-0078-1     Document Type: Review

References (43)

1. Irani A-MA, Butrus SI, Tabarra KF, Schwartz LB: Human conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis. J Allergy Clin Immunol 1990, 86: 34-39.
2. Package Insert: Optivar (azelastine hydrochloride) ophthalmic solution, 0.05%. Tewksbury, MA: Muro Pharmaceutical; 2000.
3. McTavish D, Sorkin EM: Azelastine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1989, 38: 778-800.
4. Ciprandi G, Cosentino C, Milanese M, Tosca MA: Rapid anti-inflammatory action of azelastine eyedrops for ongoing allergic reactions. Ann Allergy Asthma Immunol 2003, 90: 434-438.
5. Baggiolini M, Dahinden CA: CC chemokines in allergic inflammation. Immunol Today 1994, 15: 127-133.
6. Barney NP, Stahl J, Cook EB, Graziano FM: Cytokines, eosinophils, lymphocytes and ICAM. Acta Ophthalmol Scand Suppl 2000, 230: 7-9.
7. Ciprandi G, Pronzato C, Ricca V, et al.: Allergen specific challenge induces ICAM-1 on nasal epithelial cells in allergic subjects: relationships with early and late inflammatory phenomena. Am J Respir Crit Care Med 1994, 150: 1653-1659.
8. Lytinas M, Kempuraj D, Huang M, et al.: Azelastine's inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell induced vascular permeability: comparison with olopatadine. Allergy Asthma Proc 2002, 23: 45-51.
9. Kempuraj D, Huang M, Kandere K, et al.: Azelastine is more potent than olopatadine in inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells. Ann Allergy Asthma Immunol 2002, 88: 501-506.
10. Irani A-MA, Schwartz LB: Mast cell heterogeneity. Clin Exp Allergy 1989, 19: 143-155,
11. Anderson DF, Zhang S, Bradding P, et al.: The relative contribution of mast cell subsets to conjunctival Th2-like cytokines. Invest Ophthalmol Vis Sci 2001, 42: 995-1001.
12. Fineman S: Review of human conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis. J Allergy Clin Immunol 1990, 86: 34-39.
13. Lanier BQ, Abelson MB, Berger WE, et al.: Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge. Reprints and Commentary Series, Pragmaton Educational Grant from Alcon Labs, February 2004. Clin Ther 2002, 24: 1161-1174.
14. Duarte C, Baehre M, Gharakhanian S, et al.: Treatment of severe seasonal rhinoconjunctivitis by a combination of azelastine nasal spray and eye drops: a double blind, double placebo study. J Investig Allergol Clin Immunol 2001, 11: 34-40.
15. Spangler DL, Bensch G, Berdy GJ: Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther 2001, 23: 1272-1280.
16. Giede C, Metzenauer P, Petzold U, Ellers-Lenz B: Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis. Curr Med Res Opin 2000, 16: 153-163.
17. James IG, Campbell LM, Harrison JM, et al.: Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhinoconjunctivitis. Curr Med Res Opin 2003, 19: 313-320.
18. Giede-Tuch C, Westhoff M, Zarth A: Azelastine eye-drops in seasonal allergic conjunctivitis or rhinoconjunctivitis: a double-blind, randomized, placebo-controlled study. Allegy 1998, 53: 857-862.
19. Brockman HL, Momsen MM, Knudtson JR, et al.: Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocular Immunol Inflamm 2003, 11: 247-268.
20. Sharif NA, Xu SX: Characterization of the ocular antiallergic and antihistaminic effects of olopatadine, a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther 1996, 278: 1252-1261.
21. Yanni JM, Stephens DJ, Miller ST, et al.: The in vitro and in vivo ocular pharmacology of olopatadine, an effective anti-allergic/antihistaminic agent. J Ocular Pharmacol 1996, 12: 389-400.
22. Berdy GJ, Stoppel JO, Epstein A: Comparison of clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model. Clin Ther 2002, 24: 918-929.
23. Kamei H, Noda Y, Ishikawa K, et al.: Comparative study of acute effects of single doses of fexofenadine, olopatadine, d-chlorpheniramine and placebo on psychomotor function in healthy volunteers. Hum Psychopharmacol 2003, 18: 611-618.
24. Patanol. www.fda.gov/medwatch/SAFETY/2003/03APR_PI/Patanol_PI.pdf
25. Kempuraj D, Huang M, Kandere-Grzybowska K, et al.: Azelastine inhibits secretion of IL-6, TNF-alpha and IL-8 as well as NF-kappaB activation and intracellular calcium ion levels in normal human mast cells. Int Arch Allergy Immunol 2003, 132: 231-239.
26. Ohmori K: Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride: a new antiallergic drug. Jpn J Pharmacol 2002, 88: 379-397.
27. Fukuishi N, Matsuhisa M, Shimono T, et al.: Inhibitory effect of olopatadine on antigen-induced eosinophil infiltration and the LFA-1 and Mac-1 expression in eosinophils. Jpn J Pharmacol 2002, 88: 463-466.
28. Brodsky M: Allergic conjunctivitis and contact lenses: experience with olopatadine hydrochloride 0.1% therapy. Acta Ophthalmol Scand Suppl 2000, 230: 56-59.
29. Vogelson CT, Abelson MB, Pasquine T, et al.: Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration. Allergy Asthma Proc 2004, 25: 69-75.
30. Aguilar AJ: Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol Scand Suppl 2000, 230: 52-55.
31. Artal MN, Luna JD, Discepola M: A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%. Acta Ophthalmol Scand Suppl 2000, 230: 64-65.
32. Katelaris C, Ciprandi G, Missotten L, et al.: A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. Clin Ther 2002, 24: 1561-1576.
33. Berdy GJ, Spangler DL, Bensch GB, et al.: A comparison of the relative efficacy and clinical performance of olopatadine 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model. Clin Ther 2000, 22: 826-833.
34. Bielory L: The role of antihistamines in ocular allergy. Am J Med 2002, 113: 1S-4S.
35. Lanier BQ, Gross RD, Marks BB, et al.: Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms [summary for patients in Curr Allergy Asthma Rep. 2002 Jul;2(4):320; PMID: 12099259]. Ann Allergy Asthma Immunol 2001, 86: 641-648.
36. Abelson MB, Welch DL: An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmol Scand Suppl 2000, 230: 60-03.
37. Leonardi A, Abelson MB: Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin Ther 2003, 25: 2539-2552.
38. Lanier BQ, Abelson MB, Berger WE, et al.: Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge. Clin Ther 2002, 24: 1161-1174.
39. Sharif NA, Xu Sx, Yanni JM: Olopatadine: ligand binding and functional studies on a novel long acting H1 selective histamine antagonist and antiallergic agent for use in allergic conjunctivitis. J Ocular Pharmacol 1996, 12: 401-407.
40. Abelson MB, Loeffler O: Conjunctival allergen challenge: models in the investigation of ocular allergy. Curr Allergy Asthma Rep 2003, 3: 363-368.
41. Brockman H, Graff G, Spellman J, Yanni J: A comparison of the effects of olopatadine and ketotifen on model membranes. Acta Ophthalmol Scand Suppl 2000, 230: 10-15.
42. Bhargava A, Jackson WB, El-Defrawy SR: Ocular allergic disease. Drugs Today (Barc) 1998, 34: 957-971.
43. Bielory L: Ocular allergy guidelines: a practical treatment algorithm [review]. Drugs 2002, 62: 1611-1634.